Chronic pancreatitis

Pancrelipase Market to Reach USD 2.7 Billion, Globally, by 2031 at 4.3% CAGR: Allied Market Research

Retrieved on: 
Monday, December 5, 2022
Online, Chronic pancreatitis, Pancreatic cancer, Cystic fibrosis, Patient, Prevalence, Hospital, Employment, Incidence, Pharmacy, Growth, Bromelain, Distribution, Pharmacy Council of India, Pharmaceutical industry, Dietary supplement, Geriatrics

PORTLAND, Ore., Dec. 4, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Pancrelipase Market by Application (Chronic Pancreatitis, Cystic Fibrosis, Others), by Age (Children, Adults and Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global pancrelipase industry was estimated at $1.8 billion in 2021, and is anticipated to hit $2.7 billion by 2031, registering a CAGR of 4.3% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.

Key Points: 
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • However, as the global situation started getting back to normalcy, the pancrelipase market also restored at a slow & steady pace.
  • By region, North America contributed to nearly three-fourths of the global pancrelipase market revenue, holding the major share in 2021.

Pancrelipase Market to Reach USD 2.7 Billion, Globally, by 2031 at 4.3% CAGR: Allied Market Research

Retrieved on: 
Monday, December 5, 2022
Online, Chronic pancreatitis, Pancreatic cancer, Cystic fibrosis, Patient, Prevalence, Hospital, Employment, Incidence, Pharmacy, Growth, Bromelain, Distribution, Pharmacy Council of India, Pharmaceutical industry, Dietary supplement, Geriatrics

PORTLAND, Ore., Dec. 4, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Pancrelipase Market by Application (Chronic Pancreatitis, Cystic Fibrosis, Others), by Age (Children, Adults and Geriatrics), by Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global pancrelipase industry was estimated at $1.8 billion in 2021, and is anticipated to hit $2.7 billion by 2031, registering a CAGR of 4.3% from 2022 to 2031. The report offers an explicit analysis of the changing market trends, top segments, key investment pockets, value chains, competitive scenarios, and regional landscapes.

Key Points: 
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • Increase in the incidence of chronic pancreatitis, cystic fibrosis, and pancreatic cancer drives the growth of the global pancrelipase market.
  • However, as the global situation started getting back to normalcy, the pancrelipase market also restored at a slow & steady pace.
  • By region, North America contributed to nearly three-fourths of the global pancrelipase market revenue, holding the major share in 2021.

Dr. Joshua Tierney, MD, Commended for His Dedication to Patient Care Before and After Surgical Procedures

Retrieved on: 
Monday, April 4, 2022
Pancreas, Emergency, Stomach, List of Hindawi academic journals, Abdominal wall, Hernia, HPB, General surgery, Gallbladder, Cancer, Neoplasm, Patient, MD, Health, Technology, Hope, ERCP, Fellow, Chronic pancreatitis, Bile, Trauma, Wilms' tumor, Whipple, Medical device, Dentistry, Surveying, Medical imaging, Nebraska Panhandle

Today, Dr. Joshua Tierney was commended for his dedication to patient care before and after surgical procedures.

Key Points: 
  • Today, Dr. Joshua Tierney was commended for his dedication to patient care before and after surgical procedures.
  • Peers and patients alike consider Dr. Joshua Tierney to be one of the leading Whipple procedure surgeons, robotic hernia surgeons & robotic pancreatic surgeons in the country.
  • A surgeon isnt just somebody patients entrust with their procedure, and its also somebody they count on to provide comfort, care and support.
  • Learn more about Dr. Joshua Tierney, the conditions he treats and the surgical procedures he provides via the website: https://www.drjoshuatierney.com/

The National Pancreas Foundation Partners with Seqster to Launch a New Dynamic Patient Registry System

Retrieved on: 
Tuesday, January 11, 2022
Patient, Pancreas, Chronic pancreatitis, Technology, Research, Man, SAN, Laika (EHR testing framework), Inflammation, NPF, Hope, Incidence, Genomics, Islet, Pharmacy, CEO, Pancreatitis, Government, Pancreatic disease, Health, Pancreatic cancer, DNA, Cancer, Woman, Time, Pancreas disease in farmed salmon, View, Caregiver, Software as a service, Education, Food, Data collection, Multimedia, Prevalence, Hospital, Organization, Partnership, List of life sciences, Awareness, Pharmaceutical industry, Medical imaging

The innovative new registry powered by Seqster connects to any EHR, genomic DNA test, and wearable/remote monitoring device, providing patients with a complete longitudinal health record in real-time.

Key Points: 
  • The innovative new registry powered by Seqster connects to any EHR, genomic DNA test, and wearable/remote monitoring device, providing patients with a complete longitudinal health record in real-time.
  • "We are very excited to enter a multi-year partnership with Seqster to create a one-of-a-kind patient registry," said CEO at NPF, David Bakelman
    "We are very excited to enter a multi-year partnership with Seqster to create a one-of-a-kind patient registry that truly empowers our members.
  • Without the Seqster technology, this would have never been possible," said Chief Executive Officer at NPF, David Bakelman.
  • "Now, we can enable greater collaboration amongst researchers and our foundation, improve the quality of patient care, and significantly impact outcomes for patients with pancreatic disease."

New online community to provide important support to chronic pancreatitis patients.

Retrieved on: 
Tuesday, November 16, 2021
Health, Industry, Therapy, PERT, Chronic pancreatitis, Pancreatitis, CEO, Disease, HealthUnlocked, SVP, Research, Acute pancreatitis, LLC, Patient, Food, NHS, National Health Service (England), Pancreas, Steatorrhea, EPI, EU, Pharmaceutical industry

The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment.

Key Points: 
  • The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment.
  • Patients can join the community by following this link: https://healthunlocked.com/pancreatitis-support
    "Chronic pancreatitis is a chronic inflammatory destructive disease of the pancreas associated with multiple consequences including pancreatic exocrine insufficiency.
  • "Aimmune is committed to further understanding the impact of EPI on the quality of patients' lives with chronic pancreatitis," said Mohamed Yassine, MD.
  • Clinicians, the NHS (including NHS Choices), insurers and industry can use HealthUnlocked to link up with patients safely online.

Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis

Retrieved on: 
Tuesday, June 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Fitness & Nutrition, Clinical trials, Pancreas disorders, Medical specialties, Chronic pancreatitis, Pancreatitis, Medicine, Clinical medicine, the PACT-CP - Patient-Centric Chronic Pancreatitis Registry Study, Aimmune, Nestlé Health Science, THE PACT-CP - PATIENT-CENTRIC CHRONIC PANCREATITIS REGISTRY STUDY, AIMMUNE, NESTLé HEALTH SCIENCE

Studies such as PACT-CP will be invaluable in improving the understanding and treatment of complex disorders such as chronic pancreatitis."

Key Points: 
  • Studies such as PACT-CP will be invaluable in improving the understanding and treatment of complex disorders such as chronic pancreatitis."
  • The study was designed using input from patients and expert advisors and will track approximately 400 patients at 20 gastroenterology sites across the United States.
  • The PACT-CP Registry study is a prospective, non-interventional research study for individuals diagnosed with EPI due to CP under the care of a gastroenterologist.
  • AIMMUNE and AIMMUNE THERAPEUTICS are trademarks of Aimmune Therapeutics, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005124/en/

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Thursday, May 13, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Insufficiency

We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.

Key Points: 
  • We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.
  • Based on the clinical evidence from the combination trial to-date, we have been able to improve the nutritional status of the severe EPI patients who need the most help.
  • It turns out that the patients with the lowest baseline CFAs had the largest improvements in CFA in the study.
  • The lead therapeutic candidate is\xc2\xa0MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis,\xc2\xa0currently in two Phase 2 clinical trials.

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

Retrieved on: 
Wednesday, May 12, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Insufficiency, Pancreas, Pancreatic disease

These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.

Key Points: 
  • These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.
  • It is particularly adapted to the needs of small and medium-sized enterprises.\nAzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The lead therapeutic drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • For more information visit www.azurrx.com .\nThis press release may contain certain statements relating to future results which are forward-looking statements.

AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit

Retrieved on: 
Tuesday, May 11, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Pancreas, Lipase, Insufficiency, Anthera Pharmaceuticals

b'AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • b'AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The Company has a pipeline of three gut-restricted GI assets.
  • The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Retrieved on: 
Wednesday, March 31, 2021
Medical specialties, Digestive diseases, Pancreas disorders, Clinical medicine, Chronic pancreatitis, Exocrine pancreatic insufficiency, Cystic fibrosis, Pancreatitis, Insufficiency, Pancreas, Anthera Pharmaceuticals, Pancreatic disease

ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI).

Key Points: 
  • ET, to discuss the topline results from its Phase 2b OPTION 2 clinical trial investigating MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI).
  • An audio webcast of the conference call will be accessible via the Investors section of the AzurRx website https://azurrx.com/.
  • The OPTION 2 trial was an open-label, crossover study, conducted in 15 sites in the U.S. and Europe.
  • MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis.